Literature DB >> 16076374

Post-translational modification of Fibroblast Growth Factor 23.

Seiji Fukumoto1.   

Abstract

Fibroblast Growth Factor (FGF) 23 has been shown to play important roles in the development of hypophosphatemic rickets/osteomalacia. Complementary DNA predicts that the FGF23 protein is composed of 251 amino acids and N-terminal 24 amino acids seem to be a signal peptide. In vitro experiments indicate that a part of the FGF23 protein is processed between arginine179 and serine180. When full-length, N-terminal and C-terminal processed fragments of FGF23 were injected into mice, only the full-length FGF23 reduced serum phosphate levels indicating that the processing of FGF23 abolished its effect to cause hypophosphatemia. This processing was shown to be prevented by an inhibitor of furin indicating that the cleavage is mediated by subtilisin-like proprotein convertase. In addition to this processing, FGF23 protein seems to have O-linked glycosylation. Further studies are necessary to clarify the importance of O-glycosylation for FGF23 activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16076374     DOI: 10.1111/j.1744-9987.2005.00289.x

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  14 in total

1.  Stability and degradation of fibroblast growth factor 23 (FGF23): the effect of time and temperature and assay type.

Authors:  D El-Maouche; C E Dumitrescu; P Andreopoulou; R I Gafni; B A Brillante; N Bhattacharyya; N S Fedarko; M T Collins
Journal:  Osteoporos Int       Date:  2016-02-29       Impact factor: 4.507

2.  TGF-β-stimulated CTGF production enhanced by collagen and associated with biogenesis of a novel 31-kDa CTGF form in human corneal fibroblasts.

Authors:  Edward G Tall; Audrey M Bernstein; Noelynn Oliver; Julia L Gray; Sandra K Masur
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-04-14       Impact factor: 4.799

Review 3.  Extending the family table: Insights from beyond vertebrates into the regulation of embryonic development by FGFs.

Authors:  Sarah Tulin; Angelike Stathopoulos
Journal:  Birth Defects Res C Embryo Today       Date:  2010-09

4.  PAI-1-regulated extracellular proteolysis governs senescence and survival in Klotho mice.

Authors:  Mesut Eren; Amanda E Boe; Sheila B Murphy; Aaron T Place; Varun Nagpal; Luisa Morales-Nebreda; Daniela Urich; Susan E Quaggin; G R Scott Budinger; Gökhan M Mutlu; Toshio Miyata; Douglas E Vaughan
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-28       Impact factor: 11.205

Review 5.  Fibrous dysplasia and fibroblast growth factor-23 regulation.

Authors:  Alison M Boyce; Nisan Bhattacharyya; Michael T Collins
Journal:  Curr Osteoporos Rep       Date:  2013-06       Impact factor: 5.096

6.  Zebrafish ProVEGF-C expression, proteolytic processing and inhibitory effect of unprocessed ProVEGF-C during fin regeneration.

Authors:  Abdel-Majid Khatib; Rachid Lahlil; Nathalie Scamuffa; Marie-Andrée Akimenko; Sylvain Ernest; Abdderahim Lomri; Claude Lalou; Nabil G Seidah; Bruno O Villoutreix; Fabien Calvo; Geraldine Siegfried
Journal:  PLoS One       Date:  2010-07-02       Impact factor: 3.240

7.  Analysis of Thisbe and Pyramus functional domains reveals evidence for cleavage of Drosophila FGFs.

Authors:  Sarah Tulin; Angelike Stathopoulos
Journal:  BMC Dev Biol       Date:  2010-08-05       Impact factor: 1.978

8.  Key role of the kidney in the regulation of fibroblast growth factor 23.

Authors:  Maria L Mace; Eva Gravesen; Jacob Hofman-Bang; Klaus Olgaard; Ewa Lewin
Journal:  Kidney Int       Date:  2015-07-29       Impact factor: 10.612

Review 9.  Mineral metabolism and aging: the fibroblast growth factor 23 enigma.

Authors:  Beate Lanske; M Shawkat Razzaque
Journal:  Curr Opin Nephrol Hypertens       Date:  2007-07       Impact factor: 2.894

10.  Hyperphosphatemic familial tumoral calcinosis caused by a mutation in GALNT3 in a European kindred.

Authors:  Polina Specktor; John G Cooper; Margarita Indelman; Eli Sprecher
Journal:  J Hum Genet       Date:  2006-03-10       Impact factor: 3.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.